Viral hepatitis C - Lancet

[Guest guest]

Lancet. 2003 Dec 20;362(9401):2095-100.

Viral hepatitis C.

Poynard T, Yuen MF, Ratziu V, Lai CL.

Service d'Hepato-gastro-enterologie, Groupe Hospitalier Pitie-Salpetriere,

Universite, Paris, France. tpoynard@...

More than 170 million people worldwide are chronically infected with the

hepatitis C virus (HCV), which is responsible for more than 100000 cases of

liver cancer per year, with similar numbers of digestive haemorrhage and

ascites episodes. Major breakthroughs have been made in diagnosis and

treatment, and advances in molecular biology mean that the replicative state

of the virus can now be assessed. Genotype and serum viral load are useful

predictors of response to treatment. The combination of pegylated interferon

and ribavirin can eradicate the virus in more than 50% of patients. These

antiviral treatments reduce liver fibrosis progression and can reverse

cirrhosis. Unfortunately, even in developed countries, death due to

hepatitis C is increasing because of inadequate detection and treatment.

Publication Types:

Review

Review, Tutorial

PMID: 14697814 [PubMed - indexed for MEDLINE]

[Guest guest]

Lancet. 2003 Dec 20;362(9401):2095-100.

Viral hepatitis C.

Poynard T, Yuen MF, Ratziu V, Lai CL.

Service d'Hepato-gastro-enterologie, Groupe Hospitalier Pitie-Salpetriere,

Universite, Paris, France. tpoynard@...

More than 170 million people worldwide are chronically infected with the

hepatitis C virus (HCV), which is responsible for more than 100000 cases of

liver cancer per year, with similar numbers of digestive haemorrhage and

ascites episodes. Major breakthroughs have been made in diagnosis and

treatment, and advances in molecular biology mean that the replicative state

of the virus can now be assessed. Genotype and serum viral load are useful

predictors of response to treatment. The combination of pegylated interferon

and ribavirin can eradicate the virus in more than 50% of patients. These

antiviral treatments reduce liver fibrosis progression and can reverse

cirrhosis. Unfortunately, even in developed countries, death due to

hepatitis C is increasing because of inadequate detection and treatment.

Publication Types:

Review

Review, Tutorial

PMID: 14697814 [PubMed - indexed for MEDLINE]

[Guest guest]

Lancet. 2003 Dec 20;362(9401):2095-100.

Viral hepatitis C.

Poynard T, Yuen MF, Ratziu V, Lai CL.

Service d'Hepato-gastro-enterologie, Groupe Hospitalier Pitie-Salpetriere,

Universite, Paris, France. tpoynard@...

More than 170 million people worldwide are chronically infected with the

hepatitis C virus (HCV), which is responsible for more than 100000 cases of

liver cancer per year, with similar numbers of digestive haemorrhage and

ascites episodes. Major breakthroughs have been made in diagnosis and

treatment, and advances in molecular biology mean that the replicative state

of the virus can now be assessed. Genotype and serum viral load are useful

predictors of response to treatment. The combination of pegylated interferon

and ribavirin can eradicate the virus in more than 50% of patients. These

antiviral treatments reduce liver fibrosis progression and can reverse

cirrhosis. Unfortunately, even in developed countries, death due to

hepatitis C is increasing because of inadequate detection and treatment.

Publication Types:

Review

Review, Tutorial

PMID: 14697814 [PubMed - indexed for MEDLINE]

[Guest guest]

Lancet. 2003 Dec 20;362(9401):2095-100.

Viral hepatitis C.

Poynard T, Yuen MF, Ratziu V, Lai CL.

Service d'Hepato-gastro-enterologie, Groupe Hospitalier Pitie-Salpetriere,

Universite, Paris, France. tpoynard@...

More than 170 million people worldwide are chronically infected with the

hepatitis C virus (HCV), which is responsible for more than 100000 cases of

liver cancer per year, with similar numbers of digestive haemorrhage and

ascites episodes. Major breakthroughs have been made in diagnosis and

treatment, and advances in molecular biology mean that the replicative state

of the virus can now be assessed. Genotype and serum viral load are useful

predictors of response to treatment. The combination of pegylated interferon

and ribavirin can eradicate the virus in more than 50% of patients. These

antiviral treatments reduce liver fibrosis progression and can reverse

cirrhosis. Unfortunately, even in developed countries, death due to

hepatitis C is increasing because of inadequate detection and treatment.

Publication Types:

Review

Review, Tutorial

PMID: 14697814 [PubMed - indexed for MEDLINE]